Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public Offering

  Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public
  Offering

Business Wire

BOSTON -- July 1, 2013

Attorneys in the Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. represented Intercept Pharmaceuticals, Inc. in the completion
of its previously announced underwritten public offering of 1,730,000 shares
of its common stock at a public offering price of $33.01 per share. In
addition, the underwriters have exercised in full their option to purchase an
additional 259,500 shares of common stock at the public offering price.

Intercept Pharmaceuticals is a clinical stage biopharmaceutical company
focused on the development and commercialization of novel bile acid
therapeutics to treat chronic liver diseases. All of the shares in the
offering were sold by Intercept, with net proceeds to Intercept of
approximately $61.7 million, after deducting underwriting discounts and
commissions and estimated offering expenses.

BofA Merrill Lynch and Citigroup acted as joint book-running managers, BMO
Capital Markets acted as lead manager and Needham & Company, Wedbush PacGrow
Life Sciences and Janney Montgomery Scott acted as co-managers for the
offering.

Representing Intercept in the offering were Bill Whelan, a Member of Mintz
Levin’s Corporate & Securities Section and Co-Chair of the Life Sciences
Practice Group, Scott Samuels, a Member of the Corporate & Securities Section
and Life Sciences Practice, and Tavis Morello and Caroline Gammill, attorneys
in the firm’s Corporate & Securities Section.

Mintz Levin has served as one of the leading law firms to the life sciences
industry since the industry’s birth in the 1970s. Today, the firm advises
hundreds of businesses and other organizations in all sectors of the
industry’s ecosystem -- from start-ups looking for their first funding to
public companies with products on the market, as well as venture capital
firms, investment banks, and research and academic institutions. Mintz Levin
attorneys provide experienced counsel to clients globally in a broad range of
matters, including corporate finance and securities, mergers and acquisitions,
licensing and collaborations, intellectual property, litigation, regulatory,
employment and benefits, bankruptcy and commercial lending, immigration, and
real estate. Mintz Levin is a full-service law firm comprised of 450 attorneys
with eight offices (Boston, New York, San Diego, San Francisco, Washington,
Stamford, Los Angeles, and London) and an affiliate relationship in Israel.

For more information about Mintz Levin, please visit www.mintz.com

Contact:

Mintz Levin
Meg O’Donnell, 617-348-4956
MSODONNELL@MINTZ.COM